secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2023-03-17T23:59:59+00:00
Accession:  0001628280-23-008497
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex amends bylaws to align with universal proxy rules and DGCL changes
----------------------------------------------------------------------------

- Board amended and restated bylaws on March 16, 2023, effective immediately.
- Revised advance notice provisions for stockholder proposals and nominations.
- Updated to accommodate SEC Rule 14a-19 universal proxy rules.
- Addressed DGCL changes regarding stockholder list at meetings.
- Other administrative and clarifying changes made.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023008497/0001628280-23-008497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023008497/cdxc-20230316.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-008497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer